Home > Media KIt > News Room

Unaudited Financial Results for the Quarter ended 31st December, 2008
Sr. No. Particulars Quarter ended
31.12.2008 (Unaudited)
Quarter ended
31.12.2007 (Unaudited)
9 Months
ended 31.12.2008 (Unaudited)
9 Months
ended 31.12.2007 (Unaudited)
Year ended
31.03.2008
(Audited)
1(a) Net Sales 4838.83 2892.97 13501.26 9178.26 12599.29
(b) Other Operating Income 1.07 3.04 4.70 6.45 35.89
  Total (1a+1b) 4839.90 2896.01 13505.96 9184.71 12635.18
2 Expenditure          
  a) (Increase) / Decrease in Stock-in-Trade & Work in Progress (82.34) (110.63) (18.29) 141.50 205.12
  b) Consumption of Raw Materials 3740.51 2265.63 10209.58 6141.42 8984.59
  c) Employee Cost 475.06 407.44 1383.04 1197.86 1608.77
  d) Depreciation and Amortisation 1175.85 1187.49 3527.57 3646.45 4709.40
  e) Other Expenditure 833.55 836.46 2222.46 2334.81 2369.96
  Total 6142.63 4586.39 17324.36 13462.04 17877.84
3 Profit / (Loss) from Operations before Other Income, Interest and Exceptional Items (1-2) (1302.73) (1690.38) (3818.40) (4277.33) (5242.66)
4 Other Income          
5 Profit / (Loss) before Interest and Exceptional Items (3+4) (1302.73) (1690.38) (3818.40) (4277.33) (5242.66)
6 Interest 39.95 834.51 137.05 922.59 926.73
7 Profit / (Loss) after Interest but before Exceptional Items (5-6) (1342.68) (2524.89) (3955.45) (5199.92) (6169.39)
8 Exceptional Items -Income/(Expense)          
9 Profit / (Loss) from Ordinary Activities before Tax (7-8) (1342.68) (2524.89) (3955.45) (5199.92) (6169.39)
10 Tax Expense          
  - Fringe Benefit Tax 4.50 8.75 15.03 16.47 21.06
  - Deffered Tax          
11 Profit / (Loss) from Ordinary Activities after Tax (9-10) (1347.18) (2533.64) (3970.48) (5216.39) (6190.45)
12 Extraordinary Items-Income/(Expense)   415.78   415.78 1313.88
13 Net Profit /(Loss) for the period (11-12) (1347.18) (2117.86) (3970.48) (4800.61) (4876.57)
14 Paid-up Equity Share Capital of Face Value of Rs.2/- each 7146.06 7141.75 7146.06 7141.75 7146.06
15 Reserves excluding Revaluation reserves         60240.96
16 a) Earning Per Share before Extraordinary Items (in Rs.)          
  Basic & Diluted (0.38) (1.13) (1.11) (2.37) (2.47)
  b) Earning Per Share after Extraordinary Items (in Rs.)          
  Basic & Diluted (0.38) (0.94) (1.11) (2.19) (1.92)
17 Public Shareholding          
  Number of Shares 201964202 202715952 201964202 202715952 201964202
  Percentage of shareholding 56.52% 56.77% 56.52% 56.77% 56.52%
             

Notes:

  1. The above results were reviewed by the audit committee and have been approved by the Board of Directors in its meeting held on 19th January, 2009. A limited review of the same has been carried out by the statutory auditors.
  2. Both Sales and Raw Material consumption include inter unit transactions of Rs.494.90 Lacs for the quarter ended December 31st, 2008 (Period to date Rs.956.90 Lacs).
  3. The Company is exclusively engaged in the Pharmaceutical Business segment. Capital employed as on December 31, 2008 is Rs.60166.21 Lacs.
  4. Pending adjudication of the petition under Section 391 of Companies Act, 1956 in the Hon'ble High Court of Himachal Pradesh at Shimla in respect of Fixed Depositors and settlement with term lenders, interest of Rs. 308.15 Lacs has not been provided which has been commented upon by Statutory Auditors.
  5. Consolidated Income from Operations, Profit(Loss) after tax and EPS for the quarter ended December 31st, 2008 stands at Rs. 5256.41 Lacs, Rs.(-)1603.98 Lacs & Rs.(-) 0.45 respectively.
  6. During the Quarter, 5 shareholder complaints were received which have been attended/redressed.
For and on behalf of the Board
Place: New Delhi
Date: 19.01.2009
(Sushil Suri)
Chairman & Managing Director